Company News
Jazz Pharma Zepzelca Misses Survival Endpoint
Jazz Pharmaceuticals reported its lung cancer drug Zepzelca failed to improve overall survival in a late-stage confirmatory trial.
Median overall survival was 8.7 months for Zepzelca monotherapy and 1
